• Home
  • Inside Kyverna
  • The Science
  • Our Opportunity
  • News
  • Careers
  • Contact
Kyverna Therapeutics

News & Events

Press Releases

January 13, 2020

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

«12

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com
kyverna_logo_inv

Links

  • Home
  • News
  • Inside Kyverna
  • Careers
  • The Science
  • Contact
  • Our Opportunity

About

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. In addition to developing next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic settings, Kyverna is creating synReg T cells, a synthetic version of Regulatory T cells (Tregs), powerful natural immune cells that control immune homeostasis through multiple immunosuppressive mechanisms. By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to transform how autoimmune diseases are treated.

FOLLOW US ON SOCIAL

©2022 Kyverna Therapeutics, Inc. All rights reserved.
  • Privacy Policy